{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:17:49Z","timestamp":1792811869487,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","award":["1200.290"],"award-info":[{"award-number":["1200.290"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113695","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T08:42:39Z","timestamp":1663576959000},"page":"113695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer"],"prefix":"10.1016","volume":"155","author":[{"given":"G.D. Marijn","family":"Veerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan P.","family":"Hurkmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oomen-de Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor H.","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.E.","family":"van Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof W.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113695_bib1","unstructured":"US Food & Drug Administration label GILOTRIF (afatinib). January 2018. Reference ID 4207081."},{"key":"10.1016\/j.biopha.2022.113695_bib2","unstructured":"European Medicines Agency, Summary of Product Characteristics, GIOTRIF, July 25, 2013. Reference EMA\/491185\/2013."},{"issue":"27","key":"10.1016\/j.biopha.2022.113695_bib3","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113695_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113695_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jtho.2019.11.005","article-title":"The evolving landscape of resistance to Osimertinib","volume":"15","author":"Schoenfeld","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2022.113695_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211012361","article-title":"Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice","volume":"13","author":"Br\u00fcckl","year":"2021","journal-title":"Ther. Adv. Med Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113695_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2022.113695_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?","author":"Budha","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.113695_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918818347","article-title":"Clinically relevant drug interactions with multikinase inhibitors: a review","volume":"11","author":"Hussaarts","year":"2019","journal-title":"Ther. Adv. Med Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2022.113695_bib10","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113695_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J. Neurogastroenterol. Motil."},{"issue":"1","key":"10.1016\/j.biopha.2022.113695_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-020-00910-1","article-title":"Influence of cow's milk and esomeprazole on the absorption of Erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients","volume":"60","author":"Veerman","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.biopha.2022.113695_bib13","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/cpt.1331","article-title":"Influence of the proton pump Inhibitor Esomeprazole on the bioavailability of regorafenib: a randomized crossover pharmacokinetic study","volume":"105","author":"de Man","year":"2019","journal-title":"Clin. Pharm. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2022.113695_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1078155214527145","article-title":"Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?","volume":"21","author":"Ha","year":"2015","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"6","key":"10.1016\/j.biopha.2022.113695_bib15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","article-title":"Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC randomized clinical trial","volume":"3","author":"Chu","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2022.113695_bib16","unstructured":"DrugBank. Molecular characteristics of afatinib. 2022. \u3008https:\/\/go.drugbank.com\/drugs\/DB08916\u3009."},{"key":"10.1016\/j.biopha.2022.113695_bib17","unstructured":"European Bioinformatics Institute. Molecular characteristics of afatinib, CHEMBL1946170. 2022. \u3008https:\/\/www.ebi.ac.uk\/chembl\/compound_report_card\/CHEMBL1173655\/\u3009."},{"issue":"11","key":"10.1016\/j.biopha.2022.113695_bib18","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2022.113695_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jchromb.2019.03.011","article-title":"Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib","volume":"1113","author":"Veerman","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2022.113695_bib20","unstructured":"US Department of Health and Human Services (US National Institute of Health). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. June 27, 2017."},{"key":"10.1016\/j.biopha.2022.113695_bib21","unstructured":"European Medicines Agency, Guideline on the investigation of drug interactions. June 21, 2012. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf\u3009."},{"key":"10.1016\/j.biopha.2022.113695_bib22","unstructured":"U.S. Department of Health and Human Services, Evaluation of Gastric pHDependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications draft-Guidance for Industry. November 2020. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis\u3009."},{"issue":"12","key":"10.1016\/j.biopha.2022.113695_bib23","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40262-013-0091-4","article-title":"Pharmacokinetics of Afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours","volume":"52","author":"Wind","year":"2013","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.113695_bib24","unstructured":"Schoenfeld D. Statistical considerations for a cross-over study where the outcome is a measurement: MGH Mallinckrodt General Clinical Research Center; 2018. \u3008http:\/\/hedwig.mgh.harvard.edu\/sample_size\/js\/js_crossover_quant.html\u3009."},{"issue":"6","key":"10.1016\/j.biopha.2022.113695_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0009-9236(96)90208-8","article-title":"Interpatient Variability in Bioavailability Is Related to the Extent of Absorption: Implications for Bioavailability and Bioequivalence Studies","volume":"60","author":"Hellriegel","year":"1996","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113695_bib26","series-title":"Design and Analysis of Cross-over Trials","author":"Jones","year":"2003"},{"issue":"6","key":"10.1016\/j.biopha.2022.113695_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2022.113695_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40262-019-00844-3","article-title":"A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications","volume":"59","author":"Patel","year":"2020","journal-title":"Clin. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.113695_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00004836-200307000-00007","article-title":"Ambulatory 24-hour esophageal pH monitoring: why, when, and what to do","volume":"37","author":"Streets","year":"2003","journal-title":"J. Clin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113695_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2125.2007.02889.x","article-title":"Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole","volume":"64","author":"Sostek","year":"2007","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2022.113695_bib31","unstructured":"US Food & Drug Administration label NEXIUM (esomeprazole magnesium). December 2014. Reference ID 3675799."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:24:05Z","timestamp":1781781845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222010848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"alternative-id":["S0753332222010848"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113695","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113695"}}